Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. University of Verona, Verona, Italy

Survival: 22.3 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Italy
City/State/Province: Verona
Hospital: University of Verona
Journal: Link
Date: 11/2008

Patients: This phase 2 study involved 95 patients with hormone-refractory prostate cancer. They ranged in age from 48 to 86 years of age. Less than 20% had previously been treated with surgery or radiation.

Treatment: Patients were treated with either docetaxel or docetaxel plus estramustine phosphate. Docetaxel is a chemotherapy drug, and estramustine is a biological therapy.

Toxicity: Grade 4 toxicities (neutropenia and cardiac arrhythmia) were not very common. Grade 3 toxicities included neutropenia, anorexia, mucositis, rash, fatigue, and conjunctivitis. Grade 3 and 4 toxicities occurred in less than 5% of patients in each treatment group.

Results: The median overall survival was 22.3 months (97 weeks) in the group treated with docetaxel and 20.7 months (90 weeks) in the group treated with docetaxel plus estramustine.

Correspondence: Dr. Orazio Caffo

E-mail to a Friend Email Physician More Information